Screen2Prevent: HIV screening for teens and young adults in emergency departments
Official title: Screen2Prevent (S2P): Using Digital Health to Improve HIV Screening and Prevention for Adolescents in the Emergency Department
Run by Westat · NCT07728123 · Data updated 2026-11-12
The study tests three ways of offering HIV screening to people aged 14–24 in emergency departments to see if it helps link them to PrEP or HIV treatment using digital health tools.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 14 Years to 24 Years |
| Sex | All |
| Enrollment | 84000 (estimated) |
| Sponsor | Westat Academic / other |
| Locations | 5 sites (Tampa, Florida and 4 other locations) |
| Status | Recruiting |
| Started | June 16, 2026 |
| Main results expected | October 31, 2028 |
| Study ends | October 31, 2028 |
| Registry record updated | August 17, 2026 |
| Trial ID | NCT07728123 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adolescents and young adults aged 14–24 who present to participating EDs during the study period.
✕Probably not a fit
Individuals not at risk for HIV or not seeking care in EDs during the study period may see no direct benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Screen2Prevent tests targeted HIV screening, universal opt-in screening, and universal opt-out screening in EDs over three 8-month periods within a 24-month timeframe. All eligible patients are invited to complete a tablet-based sexual health survey to assess HIV risk, with real-time decision support for clinicians about testing and PrEP counseling or prescription. The study uses a text-message platform to share PrEP information and to enroll patients in a digital PrEP linkage system, while also collecting baseline and 3-month EHR data for comparison. Participation does not require completing the tablet, and parental consent may be applicable for minors as part of usual care. The design aims to determine which approach most effectively increases HIV testing and linkage to prevention or treatment services among adolescents and young adults seeking ED care.
Why it matters
Potential benefit: If successful, the approach could improve timely HIV detection and increase access to PrEP and ART for teens and young adults.
How similar studies have gone: Previous work in HIV screening and digital health linkage has shown promise, but this specific multi-strategy ED-based approach in adolescents is novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 14-24 years, inclusive * Present to the participating ED, regardless of chief complaint during the study period Exclusion Criteria: * None
Where it's running
-
University of South Florida
Tampa, Florida, United States Recruiting -
Emory Atlanta Adolescent Consortium
Atlanta, Georgia, United States Recruiting -
Johns Hopkins University
Baltimore, Maryland, United States Recruiting -
St. Jude Children's Research Hospital
Memphis, Tennessee, United States Recruiting -
Baylor College of Medicine
Houston, Texas, United States Recruiting
Study contacts
- Study coordinator: Erin Ricketts
- Email: erinricketts@westat.com
- Phone: 240-453-2786
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Camino HIV Prevention and Care Study
This study tests a combined legal and peer-support program to help Latin American adults in DC and the Bay Area improve HIV testing, PrEP use, and care engagement.
-
VH4367310 in healthy adults: testing single increasing doses for safety and how it behaves in the body
This study tests a single rising dose of VH4367310, a cabotegravir prodrug, to see how it behaves in the body and how safe and tolerable it is in healthy adults aged 18 to 55.
-
Online cohort of sexual and gender minorities testing digital support to boost PrEP and ART use
In Brazil, sexually and gender diverse adults are being followed online to see if weekly WhatsApp reminders help people stick to PrEP or ART.
-
Metabolic Liver Disease in People Newly Diagnosed with HIV
This study tests whether HIV-infected adults who are starting ART are more likely to develop MASLD and related liver issues than HIV-negative adults over five years.
-
Long-acting LEN/TAB/ZAB vs CAB/RPV in adults with HIV-1 who are virologically suppressed on daily ART
This study tests whether switching to a weekly-plus long-acting injectable regimen of lenacapavir, teropavimab, and zinlirvimab works as well as a two-drug injectable regimen of cabotegravir and rilpivirine for adults with HIV-1 who already have undetectable virus on daily treatment.
-
Mass Balance and Oral Bioavailability of a radiolabeled HIV drug
This early-phase study tests how the radiolabeled VH4524184 is absorbed, distributed, metabolized, and excreted in adults with HIV.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.